PF-AtlasClinical Trials › NCT01781793

Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease

Room air · Not specified

Registry ID
NCT01781793
Phase
Not specified
Status
Completed
Drug / intervention
Room air
Sponsor
University of British Columbia
Start
2013-09
Enrollment
20
Locations
1

About this trial

Exertional dyspnea is a major source of crippling distress and is the hallmark symptom of fibrotic interstitial lung disease (ILD). Due to the scientific community's poor understanding of the pathophysiological mechanisms of dyspnea there are no therapeutic interventions that consistently reduce dyspnea in this population. The investigators aim to determine the physiological mechanisms of exertional dyspnea in patients with fibrotic ILD and the impact of hyperoxia on exertional dyspnea and exercise endurance. This study will likely identify an important physiological mechanism of dyspnea in fibrotic ILD and may contribute to the development of effective therapies to reduce dyspnea in this population. The central hypothesis is that dyspnea in fibrotic ILD is primarily a result of an imbalance between the drive to breathe and the tidal volume response of the respiratory system (i.e., neuromechanical uncoupling) and that experimental reduction of neuromechanical uncoupling via hyperoxic breathing will reduce exertional dyspnea and improve exercise endurance.

View NCT01781793 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT01781793 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.